Nutra Pharma's Sales Plummet, Going Concern Doubts Intensify

TL;DR

**Nutra Pharma is a zombie company, avoid at all costs; its sales are collapsing and it has no cash.**

AI Summary

NUTRA PHARMA CORP. reported a net loss of $426,934 for the three months ended March 31, 2024, an improvement from the $592,560 net loss in the same period of 2023. Total net sales decreased significantly by 52.6% to $72,681 in Q1 2024 from $155,024 in Q1 2023, primarily due to a 65.2% drop in net sales to a related party from $100,502 to $34,949. Gross profit also declined by 65.9% to $35,197 from $103,099 year-over-year. The company continues to face substantial doubt regarding its ability to continue as a going concern, evidenced by an accumulated deficit of $75,372,408, a working capital deficit of $14,278,846, and a stockholders' deficit of $14,191,742 as of March 31, 2024. Operating expenses decreased by 34.2% to $330,506, largely due to the absence of a bad debt expense to a related party, which was $105,465 in Q1 2023. The company relies heavily on debt and equity funding, with no cash or cash equivalents reported at March 31, 2024, and December 31, 2023.

Why It Matters

Nutra Pharma's significant sales decline and persistent going concern warning signal extreme financial distress for investors. The company's reliance on debt and equity funding, coupled with its common stock being on the OTC Expert Market, severely limits its ability to raise necessary capital, making it a high-risk investment. Employees face job insecurity given the company's inability to fund operations from sales. Customers might see disruptions in product availability if the company cannot secure financing. In a competitive biotechnology and pain relief market, Nutra Pharma's struggles highlight the challenges smaller players face without robust financial backing.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt regarding our ability to continue as a going concern" due to recurring significant losses, an accumulated deficit of $75,372,408, a working capital deficit of $14,278,846, and a stockholders' deficit of $14,191,742 as of March 31, 2024. Furthermore, it reported no cash or cash equivalents at March 31, 2024, and December 31, 2023, indicating severe liquidity issues.

Analyst Insight

Investors should avoid NUTRA PHARMA CORP. given the explicit going concern warning, significant accumulated deficit, and lack of cash. The company's inability to generate sufficient sales to fund operations and its reliance on precarious debt and equity funding make it an extremely speculative and high-risk investment.

Financial Highlights

debt To Equity

N/A

revenue

$72,681

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$426,934

eps

N/A

gross Margin

48.4%

cash Position

$0

revenue Growth

-52.6%

Revenue Breakdown

Key Numbers

• $426,934 — Net Loss (Decreased from $592,560 in Q1 2023, but still a significant loss.)
• $72,681 — Total Net Sales (Decreased by 52.6% from $155,024 in Q1 2023, indicating severe revenue decline.)
• $34,949 — Net Sales to a Related Party (Decreased by 65.2% from $100,502 in Q1 2023, a major contributor to overall sales drop.)
• $35,197 — Gross Profit (Decreased by 65.9% from $103,099 in Q1 2023, reflecting poor sales performance.)
• $75,372,408 — Accumulated Deficit (Increased from $74,945,474 at December 31, 2023, highlighting ongoing losses.)
• $14,278,846 — Working Capital Deficit (Increased from $13,857,577 at December 31, 2023, worsening liquidity.)
• $14,191,742 — Stockholders' Deficit (Increased from $13,768,308 at December 31, 2023, indicating negative equity.)
• $0 — Cash and Cash Equivalents (No cash reported at March 31, 2024, or December 31, 2023, a critical liquidity issue.)
• 7,099,727,214 — Common Stock Shares Outstanding (As of December 17, 2025, indicating significant share count.)
• 52.6% — Revenue Decline (Percentage decrease in total net sales from Q1 2023 to Q1 2024.)

Key Players & Entities

• NUTRA PHARMA CORP. (company) — registrant and holding company
• ReceptoPharm, Inc. (company) — wholly-owned subsidiary conducting R&D
• Designer Diagnostics Inc. (company) — inactive wholly-owned subsidiary
• Stemsation (company) — company whose stocks Nutra Pharma invested in and sold
• $75,372,408 (dollar_amount) — accumulated deficit as of March 31, 2024
• $14,278,846 (dollar_amount) — working capital deficit as of March 31, 2024
• $14,191,742 (dollar_amount) — stockholders' deficit as of March 31, 2024
• $426,934 (dollar_amount) — net loss for the three months ended March 31, 2024
• $72,681 (dollar_amount) — total net sales for the three months ended March 31, 2024
• OTC Market Group's Expert Market (market) — where Nutra Pharma's common stock is traded, limiting capital raising

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt regarding its ability to continue as a going concern due to a significant accumulated deficit of $75,372,408, a working capital deficit of $14,278,846, and a stockholders' deficit of $14,191,742 as of March 31, 2024. The lack of cash and cash equivalents further exacerbates this risk.
• Severe Revenue Decline [high — financial]: Total net sales decreased by 52.6% to $72,681 in Q1 2024 from $155,024 in Q1 2023. This decline is heavily influenced by a 65.2% drop in sales to a related party.
• Deteriorating Gross Profit [high — financial]: Gross profit declined by 65.9% to $35,197 in Q1 2024 from $103,099 in Q1 2023, indicating that the cost of goods sold is outpacing revenue, further pressuring profitability.
• Dependence on Related Party Transactions [medium — operational]: The significant drop in sales to a related party (down 65.2%) highlights a potential over-reliance on this single customer or entity, making the company vulnerable to changes in that relationship.
• Negative Working Capital [high — financial]: The working capital deficit increased to $14,278,846 as of March 31, 2024, from $13,857,577 at the end of 2023, signaling insufficient liquid assets to cover short-term liabilities.
• Lack of Cash Reserves [high — financial]: The company reported $0 in cash and cash equivalents as of both March 31, 2024, and December 31, 2023. This critical liquidity shortage necessitates continuous reliance on external financing.
• Persistent Operating Losses [high — financial]: Despite a reduction in operating expenses by 34.2% to $330,506, the company still reported a net loss of $426,934 for Q1 2024, indicating that revenue generation is insufficient to cover costs.

Industry Context

Nutra Pharma Corp operates in the pharmaceutical and nutraceutical sectors, which are highly competitive and subject to stringent regulatory oversight. The industry is characterized by long product development cycles, significant R&D investment, and the need for continuous innovation. Companies often face challenges related to market access, pricing pressures, and intellectual property protection.

Regulatory Implications

As a pharmaceutical company, Nutra Pharma Corp is subject to extensive regulations from bodies like the FDA. Compliance with manufacturing standards, clinical trial protocols, and marketing practices is critical. Any failure to adhere to these regulations can result in significant fines, product recalls, and reputational damage, impacting its ability to operate and generate revenue.

What Investors Should Do

1. Monitor Related Party Transactions
2. Assess Funding Strategy
3. Evaluate Cost Structure Improvements
4. Scrutinize Revenue Generation Strategy

Glossary

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. If substantial doubt exists, it must be disclosed. (The company's 10-Q explicitly states substantial doubt exists, indicating a high risk of business failure.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any net gains. It represents a negative retained earnings balance. (A large and growing accumulated deficit of $75,372,408 highlights the company's long-term unprofitability.)

Working Capital

The difference between a company's current assets and current liabilities. It measures short-term financial health and operational efficiency. (A deficit of $14,278,846 indicates that the company's short-term liabilities exceed its short-term assets, posing liquidity risks.)

Stockholders' Deficit

The amount by which a company's liabilities exceed its total assets, resulting in negative equity for shareholders. (A deficit of $14,191,742 means shareholders have no residual claim on assets, reflecting the company's distressed financial state.)

Related Party

An entity or individual that has the ability to control or significantly influence the operating decisions of another entity. (A significant portion of the company's revenue decline is attributed to a drop in sales to a related party, highlighting dependency and potential conflicts of interest.)

Year-Over-Year Comparison

Compared to the prior year's first quarter, Nutra Pharma Corp. has experienced a severe 52.6% decline in total net sales, falling to $72,681 from $155,024. This revenue drop has led to a 65.9% decrease in gross profit, highlighting a significant deterioration in sales performance and profitability. While operating expenses were reduced by 34.2%, the net loss widened in absolute terms due to the sharp decline in revenue. The company's financial condition has also worsened, with increases in its accumulated deficit, working capital deficit, and stockholders' deficit, underscoring ongoing financial distress.

Filing Documents

• form10-q.htm (10-Q) — 1350KB
• ex31-1.htm (EX-31.1) — 19KB
• ex32-1.htm (EX-32.1) — 8KB
• 0001493152-25-028202.txt ( ) — 9423KB
• nphc-20240331_pre.xml (EX-101.PRE) — 411KB
• nphc-20240331.xsd (EX-101.SCH) — 64KB
• nphc-20240331_cal.xml (EX-101.CAL) — 67KB
• nphc-20240331_def.xml (EX-101.DEF) — 303KB
• nphc-20240331_lab.xml (EX-101.LAB) — 488KB
• form10-q_htm.xml (XML) — 1501KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION F-1

Financial Statements

Item 1. Financial Statements F-1 Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023 F-1 Condensed Consolidated Statements of Operations for the Three months ended March 31, 2024 and 2023 (Unaudited) F-2 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Three months ended March 31, 2024 and 2023 (Unaudited) F-3 Condensed Consolidated Statements of Cash Flows for the Three months ended March 31, 2024 and 2023 (Unaudited) F-4 Notes to Condensed Consolidated Financial Statements (Unaudited) F-5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 4

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 9

Controls and Procedures

Item 4. Controls and Procedures 9

OTHER INFORMATION

PART II. OTHER INFORMATION 10

Legal Proceedings

Item 1. Legal Proceedings 10

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 11

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 11

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 11

Other Information

Item 5. Other Information 11

Exhibits

Item 6. Exhibits 11 2 Nutra Pharma Corp ("Nutra Pharma") and its wholly owned subsidiary, ReceptoPharm, Inc. ("ReceptoPharm"), are referred to herein as "we", "our" or "us" (ReceptoPharm is also individually referred to herein). Forward Looking Statements This Quarterly Report on Form 10–Q for the period ending March 31, 2024, contains forward–looking statements that involve risks and uncertainties, as well as assumptions that if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward–looking statements. The words or phrases "would be," "will allow, "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward–looking statements." We are subject to risks detailed in Item 1(a). All statements other than statements of historical fact are statements that could be deemed forward–looking statements, including: (a) any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; and (b) any statements of the plans, strategies and objectives of management for future operations; and (c) any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward–looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. 3 PART I. FINANCIAL INFORMATION Item 1. Financial Statements NUTRA PHARMA CORP. Condensed Consolidated Balance Sheets March 31, December 31, 2024 2023 (Unaudited) ASSETS Current assets: Cash $ - $ - Accounts receivable 22,093 22,433 Inventory, current portion 18,605 19,544 Other receivable 5,000 5,000 Convertible notes receivable, net of discount 9,900 6,600 Receivable from sale of

View Full Filing

View this 10-Q filing on SEC EDGAR